C. diff Testing
A previously uncommon strain of C. difficile has become more resistant and has emerged as a cause of geographically dispersed outbreaks of C. diff infections (CDI) in the U.S. and Europe. With the epidemiology changing, infections are affecting nontraditional populations and creating the need for a C. diff test that can provide early detection.
According to the Centers for Disease Control and Prevention (CDC), early diagnosis and treatment is critical in reducing severe outcomes. CDI is the 4th most common nosocomial disease reported to the CDC and can increase length of stay by one to two weeks with an additional cost of $3,669 to $7,234 per patient hospitalization.2,3
The demand for reliable C. diff testing is on the rise as the incidence continues to increase. That's why Remel offers two rapid solutions to help meet all your C. diff testing needs.
Xpect® C. difficile Toxin A/B
Xpect® Clostridium difficile Toxin A/B is an easy-to-use rapid test that delivers accurate results within 20 minutes.
- Excellent clinical sensitivity and specificity
- No specimen preparation required
- Simple 3-step procedure with minimal hands-on time
ProSpecT™ C. difficile Toxin A/B
ProSpecT™ Clostridium difficile Toxin A/B is a microplate assay designed to handle higher volume testing with results available within 100 minutes.
- Excellent clinical performance
- Cary Blair transport option
- Room temperature incubation
- True colorless negatives
- Common procedure, common reagents
References
- Jarvis, W.R., et. al. American Journal of Infection Control; 2009; 37:263-70.
- Dubberke, E.R., and Wertheimer A.I. Infection Control and Hospital Epidemiolgy; 2009; 30:57-66.
- Vonberg, R.P., et. al. Journal of Hospital Infection; 2008; 70:15-20.